12.30
1.59%
-0.28
前日終値:
$12.58
開ける:
$12.53
24時間の取引高:
27,706
Relative Volume:
0.05
時価総額:
$771.52M
収益:
-
当期純損益:
$-153.16M
株価収益率:
-3.6499
EPS:
-3.37
ネットキャッシュフロー:
$-134.48M
1週間 パフォーマンス:
-19.08%
1か月 パフォーマンス:
-23.58%
6か月 パフォーマンス:
-46.55%
1年 パフォーマンス:
+43.12%
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
CGEM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CGEM | 12.33 | 771.52M | 0 | -153.16M | -134.48M | -3.37 |
VRTX | 446.42 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 586.49 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.16 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.51 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-05-01 | 開始されました | Stifel | Buy |
2024-04-15 | 開始されました | William Blair | Outperform |
2024-02-15 | 開始されました | Wedbush | Outperform |
2023-06-15 | 開始されました | TD Cowen | Outperform |
2022-11-21 | 開始されました | BTIG Research | Buy |
2021-04-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-02-02 | 開始されました | Evercore ISI | Outperform |
2021-02-02 | 開始されました | Morgan Stanley | Equal-Weight |
2021-02-02 | 開始されました | SVB Leerink | Outperform |
2021-02-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cullinan Therapeutics Inc (CGEM) 最新ニュース
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook - TipRanks
What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings? - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat
Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada
Cullinan advances lupus treatment with new clinical trial - Investing.com
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India
Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times
Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com
Cullinan Therapeutics Inc (CGEM) Quarterly 10-Q Report - Quartzy
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cullinan Therapeutics Advances Pipeline Despite $40.6M Loss; Maintains $639M Cash Position | CGEM Stock News - StockTitan
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan
Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat
FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat
Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Newco trend watch: Clusters of launches point to areas undergoing derisking - BioCentury
cullinan oncology, inc. Earnings dates - RTTNews
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat
Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat
Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com
Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan
How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News
Cullinan Therapeutics Inc [CGEM] Records 200-Day SMA of $17.94 - Knox Daily
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Algert Global LLC Reduces Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
The Potential Rise in the Price of Cullinan Therapeutics Inc (CGEM) following insiders activity - Knox Daily
Metric Deep Dive: Understanding Cullinan Therapeutics Inc (CGEM) Through its Ratios - The Dwinnex
Results from Cullinan Therapeutics Inc (CGEM) show potential - US Post News
Perceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
Lynx1 Capital Management LP Buys New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - SETE News
Deerfield Management Company L.P. Series C Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
Quarterly Metrics: Quick and Current Ratios for Cullinan Therapeutics Inc (CGEM) - The Dwinnex
CGEM’s Debt-to-Equity Ratio at 0.00: What It Means for Cullinan Therapeutics Inc’s Future - The InvestChronicle
Paradigm Capital Management Inc. NY Has $39.46 Million Stock Holdings in Concentrix Co. (NASDAQ:CNXC) - MarketBeat
Cullinan Therapeutics Inc (CGEM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):